Fate Therapeutics Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fate Therapeutics stock.
View analyst ratings for Fate Therapeutics or view top-rated stocks.

Wall Street analysts have given Fate Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fate Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Fate Therapeutics.

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The biopharmaceutical company earned $11.14 million during the quarter, compared to analyst estimates of $7.07 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 26.48% and a negative net margin of 461.69%.
View Fate Therapeutics' earnings history.

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FATE shares have increased by 244.3% and is now trading at $81.90.
View which stocks have been most impacted by COVID-19.

14 brokers have issued 12 month price targets for Fate Therapeutics' shares. Their forecasts range from $76.00 to $145.00. On average, they expect Fate Therapeutics' stock price to reach $111.18 in the next twelve months. This suggests a possible upside of 35.7% from the stock's current price.
View analysts' price targets for Fate Therapeutics or view top-rated stocks among Wall Street analysts.

2 employees have rated Fate Therapeutics CEO Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among Fate Therapeutics' employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Fate Therapeutics include Seagen (SGEN), Bio-Techne (TECH), Novozymes A/S (NVZMY), argenx (ARGX), Novavax (NVAX), QIAGEN (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Exelixis (EXEL), Vir Biotechnology (VIR), Recursion Pharmaceuticals (RXRX) and Halozyme Therapeutics (HALO).
View all of FATE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Redmile Group LLC (13.78%), BlackRock Inc. (7.63%), ARK Investment Management LLC (6.97%), Price T Rowe Associates Inc. MD (3.35%), Bellevue Group AG (2.35%) and Janus Henderson Group PLC (2.02%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko, Redmile Group, Llc and Yu-Waye Chu.
View institutional ownership trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Victory Capital Management Inc., Price T Rowe Associates Inc. MD, Grosvenor Holdings L.L.C., Deerfield Management Company L.P. Series C, UBS Asset Management Americas Inc., D. E. Shaw & Co. Inc., and Eversept Partners LP. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko, and Yu-Waye Chu.
View insider buying and selling activity for Fate Therapeutics or view top insider-selling stocks.

FATE stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Lone Pine Capital LLC, BlackRock Inc., Darwin Global Management Ltd., Ameriprise Financial Inc., Redmile Group LLC, Credit Suisse AG, and Morgan Stanley.
View insider buying and selling activity for Fate Therapeutics or or view top insider-buying stocks.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FATE stock can currently be purchased for approximately $81.90.

Fate Therapeutics has a market capitalization of $7.70 billion and generates $31.43 million in revenue each year. The biopharmaceutical company earns $-173,390,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

Fate Therapeutics employs 314 workers across the globe.

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Fate Therapeutics is headquartered at 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]